Interleukin-11 in patients with chronic hepatitis C and advanced liver disease who have been nonresponsive to antiviral therapy

2003 ◽  
Vol 124 (4) ◽  
pp. A768
Author(s):  
Eric J. Lawitz ◽  
Thomas Casey ◽  
Norma S. Cantu
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Advanced Liver Disease ◽  
Interleukin 11

scholarly journals Advanced liver disease in Russian children and adolescents with chronic hepatitis C

2019 ◽  
Vol 26 (7) ◽  
pp. 881-892 ◽  
Author(s):  
Anna Turkova ◽  
Galina V. Volynets ◽  
Siobhan Crichton ◽  
Tamara A. Skvortsova ◽  
Victoria N. Panfilova ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Children And Adolescents ◽  
Chronic Hepatitis C ◽  
Advanced Liver Disease

A Review on the Use of Eltrombopag in Patients with Advanced Liver Disease

2009 ◽  
Vol 1 ◽  
pp. CMT.S2267
Author(s):  
Edoardo G. Giannini ◽  
Alfredo Greco ◽  
Vincenzo Savarino
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Treatment ◽  
Pegylated Interferon ◽  
Severe Thrombocytopenia ◽  
Current Standard ◽  
Advanced Liver Disease ◽  
Orally Bioavailable

Thrombocytopenia is the most common hematological abnormality in patients with chronic, advanced liver disease. In these patients, the presence of severe thrombocytopenia is an obstacle to the performance of invasive diagnostic and therapeutic procedures, and the current standard treatment for these patients is platelet transfusions, a remedy whose characteristics are far from being ideal. Furthermore, thrombocytopenia in patients with chronic hepatitis C virus infection may render the patients ineligible to antiviral treatment or may limit its efficacy because of premature discontinuation. Although the cause of thrombocytopenia in patients with chronic liver disease is likely multi-factorial, decreased thrombopoietin production by the liver undoubtedly plays a significant role. In this regard, eltrombopag, a non-peptide, orally bioavailable thrombopoietin receptor agonist has been shown to safely increase platelet count in a dose-dependent fashion in both healthy subjects and thrombocytopenic patients with chronic hepatitis C. Furthermore, in this latter group of patients, it has been shown to be superior to placebo in counteracting the myelosuppressive effect of short-term pegylated interferon treatment.

SVR reduces ethnic disparities in progression to advanced liver disease in patients with chronic hepatitis C

2017 ◽  
Vol 66 (1) ◽  
pp. S283-S284
Author(s):  
A.K. Le ◽  
C. Zhao ◽  
J. Hoang ◽  
L.A. Yasukawa ◽  
J. Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Ethnic Disparities ◽  
Advanced Liver Disease
Sign in / Sign up

Export Citation Format

Share Document